An active extract of cyperus rotundus and its preparation method and application in preventing and treating scalp and hair related diseases
Patent Information
- Application Number
- CN202611426370.0
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Filing Date
- 2026-09-15
- Publication Date
- 2026-10-20
AI Technical Summary
[0005]尽管香附具备与脱发防治高度契合的多靶点药理基础，且在传统外用复方中偶有配伍应用，但现有技术仍存在明显缺陷：现有应用多以香附粗提物或原生药粉直接使用，有效成分利用率低；缺少对毛囊周期调控、毛乳头细胞增殖等相关作用机制的系统研究，药理机制不明确；同时香附多作为复方辅助成分使用，未见以香附活性提取物为核心功效成分的产品与专门技术，其在防治头皮与毛发相关疾病中的独立应用价值未得到充分重视与开发
[0030]本发明发现，香附总提取物的弱极性萃取部位（如石油醚萃取部位）具有显著的促进人毛囊真皮乳头细胞增殖的活性；并且，该香附总提取物的弱极性萃取部位与香附总提取物的水相部位或中强极性萃取部位（如正丁醇萃取部位）还具有协同促进人毛囊真皮乳头细胞增殖的活性。本领域技术人员知道，毛囊真皮乳头细胞是位于毛囊基底部的核心功能调控细胞，对毛囊生长周期启动、毛囊干细胞活化、毛发生长维持具有决定性作用。因此，上述香附活性提取物在制备用于促进毛囊修复、促进毛发生长以及预防或治疗因毛囊再生能力降低所致疾病的产品方面具有良好的应用前景。
Smart Images
Figure SMS_1
Abstract
Description
Technical Field
[0001] This invention belongs to the field of natural plant extracts, specifically relating to an active extract of Cyperus rotundus, its preparation method, and its application in the prevention and treatment of scalp and hair-related diseases. Background Technology
[0002] Scalp and hair-related diseases are a group of highly prevalent skin conditions that seriously affect patients' appearance and mental health. Clinically, androgenetic alopecia, alopecia areata, seborrheic alopecia, and telogen effluvium are the most common. Their core pathological manifestations include disordered hair follicle growth cycle, miniaturization of hair follicles, impaired microcirculation in hair follicles, chronic scalp inflammation, and oxidative stress damage, ultimately leading to thinning, loss, dryness, and growth inhibition of hair. Currently, the mainstream clinical treatment methods are still mainly chemical drugs, such as topical minoxidil, oral finasteride, and JAK inhibitors. However, these generally have drawbacks such as limited efficacy, high relapse rate, strong local irritation, systemic side effects, and questionable safety with long-term use, making it difficult to meet the clinical and consumer needs for safe, long-lasting, and gentle treatments.
[0003] Traditional Chinese medicine has a long history in the prevention and treatment of hair diseases. Herbal ingredients such as arborvitae leaves, Polygonum multiflorum, ginseng, angelica, and Cyperus rotundus have become core active ingredients in hair loss prevention and hair growth cosmetics and drugs, possessing advantages such as being natural, gentle, and having synergistic effects on multiple targets, and are increasingly becoming research hotspots. Among them, Cyperus rotundus L., the dried rhizome of the sedge plant Cyperus rotundus, is a classic qi-regulating herb. It has a pungent and slightly bitter taste, is neutral in nature, and enters the liver, spleen, and triple burner meridians. It has the effects of soothing the liver and relieving depression, regulating qi and relieving chest tightness, and regulating menstruation and relieving pain. It is known as the "general manager of qi diseases and the commander-in-chief of gynecology," and is widely used in various symptoms caused by qi stagnation and blood stasis, and liver qi stagnation.
[0004] Modern pharmacological studies have confirmed that Cyperus rotundus is rich in chemical components, mainly containing volatile oils (sesquiterpenes and monoterpenes), flavonoids, alkaloids, triterpenes, sterols, phenolic acids, and other active ingredients. Among them, α-cyperone, cyperene, isolongenone, luteolin, and quercetin are key pharmacological substances. Its pharmacological effects cover multiple dimensions, including analgesia, anti-inflammation, antioxidation, endocrine regulation, microcirculation improvement, antibacterial, and neuroprotection. Cyperus rotundus extract and volatile oil can inhibit the release of inflammatory mediators such as NO, TNF-α, IL-6, and COX-2, reducing local inflammation. Flavonoids and phenolic components can scavenge free radicals, increase the activity of antioxidant enzymes such as SOD and GSH-Px, and alleviate oxidative stress damage. Sesquiterpenes such as α-cyperone can regulate smooth muscle contraction, improve local blood flow, and exert anti-anxiety and antidepressant effects by regulating monoamine neurotransmitters and the HPA axis. Emotional disorders and liver qi stagnation are important inducing factors for hair loss. In addition, Cyperus rotundus extract can promote gastrointestinal motility and improve nutrient absorption, indirectly providing nutritional support for hair follicles; its antibacterial activity has an inhibitory effect on scalp pathogens such as Staphylococcus aureus, which helps to improve the scalp microecology and reduce inflammatory damage to hair follicles.
[0005] Although Cyperus rotundus possesses a multi-target pharmacological basis that is highly compatible with the prevention and treatment of hair loss, and is occasionally used in combination with traditional topical compound prescriptions, existing technologies still have significant shortcomings: current applications mostly use crude extracts or raw powder of Cyperus rotundus directly, resulting in low utilization of effective ingredients; there is a lack of systematic research on the mechanisms of action related to hair follicle cycle regulation and dermal papilla cell proliferation, and the pharmacological mechanisms are unclear; at the same time, Cyperus rotundus is mostly used as an auxiliary ingredient in compound prescriptions, and there are no products or specialized technologies with Cyperus rotundus active extracts as the core active ingredient, and its independent application value in the prevention and treatment of scalp and hair-related diseases has not been fully valued and developed.
[0006] In summary, there is an urgent need for natural, safe, efficient, and multi-targeted plant-based active ingredients in the prevention and treatment of scalp and hair-related diseases. Cyperus rotundus, with its unique comprehensive pharmacological advantages including anti-inflammatory, antioxidant, microcirculation-improving, endocrine-regulating, and anti-anxiety / depression effects, possesses enormous potential to become a core ingredient for the next generation of hair loss prevention and hair growth. Therefore, developing a Cyperus rotundus active extract with polar fractional enrichment, a stable preparation process, and targeting of the hair follicle and scalp microenvironment, along with its standardized preparation method, and systematically applying it to the prevention and treatment of scalp and hair-related diseases such as androgenetic alopecia, alopecia areata, seborrheic alopecia, scalp inflammation, and dry and thinning hair, has significant clinical value and market prospects, and is a key technical problem that this invention urgently needs to solve. Summary of the Invention
[0007] The first objective of this invention is to provide an active extract of Cyperus rotundus, and the second objective is to provide the application of the active extract of Cyperus rotundus in the preparation of products for the prevention or treatment of diseases caused by reduced hair follicle regeneration capacity.
[0008] The above-mentioned objective of this invention is achieved through the following technical solution:
[0009] This invention provides an active extract of Cyperus rotundus:
[0010] The active extract of Cyperus rotundus includes a weakly polar extract fraction of the total extract of Cyperus rotundus; the preparation method of the weakly polar extract fraction includes the following steps: take the total extract of Cyperus rotundus, add water to make an aqueous suspension, extract with a weakly polar organic solvent, collect the extract, concentrate and dry to obtain the weakly polar extract fraction; the weakly polar organic solvent is selected from one or more of petroleum ether, n-hexane, and cyclohexane.
[0011] The preparation method of the total extract of Cyperus rotundus includes the following steps: taking Cyperus rotundus, extracting it with an alcohol-containing aqueous solution, and concentrating the extract to obtain the total extract of Cyperus rotundus; the volume percentage concentration of alcohol in the alcohol-containing aqueous solution is not less than 60%, 61%, 62%, 63%, 64%, 65%, 66%, 67%, 68%, 69%, 70%, 71%, 72%, 73% or 74%, and not higher than 76%, 77%, 78%, 79%, 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89% or 90%;
[0012] The alcohol is selected from one or more of ethanol and methanol.
[0013] In one specific embodiment, the volume percentage concentration of ethanol in the alcohol-containing aqueous solution is 75%. However, those skilled in the art know that similar extraction effects can be achieved using alcohol-containing aqueous solutions or methanol-containing aqueous solutions, or methanol / ethanol mixed aqueous solutions, with volume percentage concentrations of 60%, 61%, 62%, 63%, 64%, 65%, 66%, 67%, 68%, 69%, 70%, 71%, 72%, 73%, 74%, 76%, 77%, 78%, 79%, 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, or 90%. In one specific embodiment, petroleum ether is used as the weakly polar organic solvent. However, those skilled in the art know that similar extraction effects can be achieved using n-hexane or cyclohexane, which have similar polarities.
[0014] Preferably, the Cyperus rotundus active extract further comprises an aqueous fraction of the total Cyperus rotundus extract; the preparation method of the aqueous fraction includes the following steps: taking the total Cyperus rotundus extract, adding water to make an aqueous suspension, extracting sequentially with a weakly polar organic solvent, a moderately polar organic solvent, and a moderately strong polar organic solvent, collecting the remaining aqueous suspension, concentrating and drying to obtain the aqueous fraction;
[0015] The weakly polar organic solvent is selected from one or more of petroleum ether, n-hexane, and cyclohexane; the moderately polar organic solvent is selected from one or more of ethyl acetate, chloroform, and dichloromethane; and the moderately strong polar organic solvent is selected from one or more of n-butanol, isobutanol, and sec-butanol.
[0016] In one specific embodiment, the composition of the weakly polar extraction fraction and the aqueous phase fraction has a synergistic effect in promoting the proliferation of human hair follicle dermal papillary cells; in one specific embodiment, petroleum ether is selected as the weakly polar organic solvent, but those skilled in the art know that similar extraction effects can be achieved by using n-hexane or cyclohexane with similar polarity; in one specific embodiment, ethyl acetate is selected as the medium polar organic solvent, but those skilled in the art know that similar extraction effects can be achieved by using chloroform or dichloromethane with similar polarity; in one specific embodiment, n-butanol is selected as the medium-strong polar organic solvent, but those skilled in the art know that similar effects can be achieved by using isobutanol or sec-butanol with similar polarity.
[0017] Preferably, the mass ratio of the weakly polar extract fraction to the aqueous phase fraction in the Cyperus rotundus active extract is 1:(0.5~2.5); more preferably, the mass ratio of the weakly polar extract fraction to the aqueous phase fraction in the Cyperus rotundus active extract is 1:(1~2). In one specific embodiment, a composition of the weakly polar extract fraction and the aqueous phase fraction with a mass ratio of 1:1 or 1:2 has a synergistic effect in promoting the proliferation of human hair follicle dermal papillary cells.
[0018] Preferably, the Cyperus rotundus active extract further comprises a medium-to-strong polarity extract fraction of the total Cyperus rotundus extract; the preparation method of the medium-to-strong polarity extract fraction includes the following steps: take the total Cyperus rotundus extract, add water to make an aqueous suspension, and extract sequentially using a weakly polar organic solvent, a medium-polar organic solvent, and a medium-to-strong polar organic solvent, collect the medium-to-strong polar organic solvent extract, concentrate and dry it to obtain the medium-to-strong polarity extract fraction;
[0019] The weakly polar organic solvent is selected from one or more of petroleum ether, n-hexane, and cyclohexane; the moderately polar organic solvent is selected from one or more of ethyl acetate, chloroform, and dichloromethane; and the moderately strong polar organic solvent is selected from one or more of n-butanol, isobutanol, and sec-butanol.
[0020] In one specific embodiment, the composition of the weakly polar extraction fraction and the medium-to-strong polar extraction fraction has a synergistic effect in promoting the proliferation of human hair follicle dermal papillary cells; in one specific embodiment, petroleum ether is selected as the weakly polar organic solvent, but those skilled in the art know that similar extraction effects can be achieved by using n-hexane or cyclohexane with similar polarity; in one specific embodiment, ethyl acetate is selected as the medium-polar organic solvent, but those skilled in the art know that similar extraction effects can be achieved by using chloroform or dichloromethane with similar polarity; in one specific embodiment, n-butanol is selected as the medium-to-strong polar organic solvent, but those skilled in the art know that similar effects can be achieved by using isobutanol or sec-butanol with similar polarity.
[0021] Preferably, the mass ratio of the weakly polar extract to the medium-strong polar extract in the Cyperus rotundus active extract is 1:(0.5~2.5); more preferably, the mass ratio of the weakly polar extract to the medium-strong polar extract in the Cyperus rotundus active extract is 1:(1~2). In one specific embodiment, a composition of weakly polar extract and medium-strong polar extract in a mass ratio of 1:1 or 1:2 has a synergistic effect in promoting the proliferation of human hair follicle dermal papillary cells.
[0022] This invention provides the application of the above-mentioned Cyperus rotundus active extract in the preparation of products that promote hair follicle repair, or in the preparation of products that promote hair growth, or in the preparation of products that prevent or treat diseases caused by reduced hair follicle regeneration capacity. In one specific embodiment, the active ingredient in the above-mentioned Cyperus rotundus active extract has the activity of promoting / synergistically promoting the proliferation of human hair follicle dermal papilla cells. Those skilled in the art know that hair follicle dermal papilla cells are core functional regulatory cells located at the base of the hair follicle, playing a decisive role in the initiation of the hair follicle growth cycle, the activation of hair follicle stem cells, and the maintenance of hair growth. Therefore, those skilled in the art can expect that the above-mentioned Cyperus rotundus active extract can promote hair follicle repair, promote hair growth, and prevent or treat diseases caused by reduced hair follicle regeneration capacity.
[0023] Preferably, the disease caused by reduced hair follicle regeneration capacity is selected from one or more of scarring alopecia, non-scarring alopecia, and hereditary hair diseases;
[0024] in:
[0025] Cicatricial alopecia is selected from one or more of the following: lichen planus of hair, discoid lupus erythematosus, frontal fibrosis, folliculitis alopecia, scalp abscess dissecting folliculitis, centri-central cicatricial alopecia, mucinous alopecia, keratosis pilaris alopecia, classic pseudoalopecia areata, and secondary cicatricial alopecia.
[0026] Non-scarring alopecia is selected from one or more of the following: androgenetic alopecia, alopecia areata, telogen effluvium, anagen effluvium, postpartum alopecia, and trichotillomania.
[0027] Hereditary hair disorders are selected from one or more of the following: Marie Unna hereditary hypotrichosis, congenital alopecia, hypotrichosis with papules, and hypotrichosis.
[0028] Preferably, the product is a pharmaceutical, cosmetic, health product, or functional food. Taking pharmaceuticals and cosmetics as examples, the above-mentioned Cyperus rotundus active extract can be developed into various pharmaceutical and cosmetic dosage forms such as liniments, hair growth solutions, shampoos, and scalp serums.
[0029] Beneficial effects:
[0030] This invention discovers that the weakly polar extract fraction (such as the petroleum ether extract fraction) of the total extract of Cyperus rotundus exhibits significant activity in promoting the proliferation of human dermal papilla cells. Furthermore, this weakly polar extract fraction, along with the aqueous or moderately polar extract fraction (such as the n-butanol extract fraction), also possesses synergistic activity in promoting the proliferation of human dermal papilla cells. Those skilled in the art know that dermal papilla cells are core functional regulatory cells located at the base of the hair follicle, playing a decisive role in initiating the hair follicle growth cycle, activating hair follicle stem cells, and maintaining hair growth. Therefore, the above-mentioned active extract of Cyperus rotundus shows promising application prospects in the preparation of products for promoting hair follicle repair, promoting hair growth, and preventing or treating diseases caused by reduced hair follicle regeneration capacity. Detailed Implementation
[0031] The substantive content of the present invention will be described in detail below with reference to specific embodiments. However, those skilled in the art should know that the scope of protection of the present invention should not be limited to these specific embodiments.
[0032] Example 1: Cyperus rotundus extraction and fractional extraction based on polarity
[0033] I. Experimental Materials
[0034] The Cyperus rotundus was purchased from the Bozhou Traditional Chinese Medicine Market and identified by Professor Huang Qing of the School of Traditional Chinese Medicine at China Pharmaceutical University as the dried rhizome of Cyperus rotundus, a plant in the Cyperaceae family.
[0035] Water was standard laboratory water, and ethanol, petroleum ether, ethyl acetate, and n-butanol were standard analytical grade reagents.
[0036] II. Experimental Methods and Results
[0037] After chopping Cyperus rotundus, it was first soaked in an ethanol aqueous solution with a volume concentration of 75% for 24 hours, and then extracted by ultrasound at 50°C for 1 hour. The filtrate was collected by filtration, and the residue was extracted by ultrasound twice more. The three filtrates were combined and concentrated to dryness under reduced pressure to obtain the total extract of Cyperus rotundus (CR).
[0038] The total extract of Cyperus rotundus was fractionated by polarity extraction using conventional methods in the art. Specifically, water was added to the total extract of Cyperus rotundus, and the mixture was stirred to form a homogeneous extract suspension. The extract suspension was then extracted sequentially with petroleum ether (equal volume × 3 times), ethyl acetate (equal volume × 3 times), and water-saturated n-butanol (equal volume × 3 times). The petroleum ether, ethyl acetate, and n-butanol extracts and the remaining suspension were concentrated to dryness under reduced pressure to obtain the petroleum ether fraction (CRP), ethyl acetate fraction (CRE), n-butanol fraction (CRB), and water fraction (CRW), which were then dried and stored for later use.
[0039] Example 2: Effect on dermal papilla cell proliferation
[0040] I. Experimental Materials
[0041] Immortalized human hair follicle dermal papillary cells (hereinafter referred to as human hair papillary cells) were purchased from ABM in Canada.
[0042] DMEM culture medium was purchased from Zhejiang Meisen; fetal bovine serum was purchased from Gibco, USA; penicillin-streptomycin was purchased from Suzhou NCM; and the CCK-8 kit was purchased from Nanjing Vazyme.
[0043] The total extract of Cyperus rotundus (CR) and its petroleum ether fraction (CRP), ethyl acetate fraction (CRE), n-butanol fraction (CRB), and aqueous fraction (CRW) were prepared according to the method in Example 1.
[0044] II. Test Methods
[0045] 1. Culture medium preparation
[0046] Basic culture medium: DMEM medium containing 1% penicillin-streptomycin, used to prepare drug-containing culture medium.
[0047] Complete culture medium: DMEM medium containing 10% fetal bovine serum and 1% penicillin-streptomycin, used for cell culture.
[0048] 2. Cell Culture
[0049] Human dermal papilla cells were cultured in a 37°C, 5% CO2 incubator using complete culture medium.
[0050] 3. The effects of different extracts on the proliferation activity of human dermal papilla cells were detected using the CCK-8 assay.
[0051] Human dermal papilla cells were cultured in complete culture medium. When the cell confluence reached 80%–90%, they were injected at a dose of 1×10⁻⁶. 4Cells were seeded at a density of [number] cells / well in 96-well plates and cultured for 24 h until adherence. The culture medium was gently aspirated from each well, and 100 μL of drug-containing medium was added to each well for further incubation for 48 h. The culture medium was then gently aspirated from each well, and 100 μL of CCK-8 working solution diluted 10-fold with basal medium was added to each well. The plates were incubated at 37°C for 2 h, and the absorbance at 450 nm was measured using a microplate reader. Blank wells (containing no cells and no drug) and control wells (containing cells and no drug) were also included.
[0052] Cell viability (%) = [(As − Ab) / (Ac − Ab)] × 100%
[0053] As represents the absorbance of the experimental well, Ac represents the absorbance of the control well, and Ab represents the absorbance of the blank well.
[0054] The experimental groups incubated with drug-containing culture medium included:
[0055] CR group: basal culture medium containing CR at a final concentration of 12.5, 25 or 50 μg / mL;
[0056] CRP group: basal medium containing CRP at a final concentration of 12.5, 25 or 50 μg / mL;
[0057] CRE group: basal medium containing CRE at a final concentration of 12.5, 25 or 50 μg / mL;
[0058] CRB group: basal medium containing CRB at a final concentration of 12.5, 25 or 50 μg / mL;
[0059] CRW group: basal medium containing CRW at a final concentration of 12.5, 25 or 50 μg / mL;
[0060] CRP-CRE combination group: basal medium containing a final concentration of 12.5 μg / mL CRP + 12.5 μg / mL CRE, or basal medium containing a final concentration of 12.5 μg / mL CRP + 25 μg / mL CRE;
[0061] CRP-CRB combination group: basal medium containing a final concentration of 12.5 μg / mL CRP + 12.5 μg / mL CRB, or basal medium containing a final concentration of 12.5 μg / mL CRP + 25 μg / mL CRB;
[0062] CRP-CRW combination group: basal medium containing 12.5 μg / mL CRP + 12.5 μg / mL CRW, or basal medium containing 12.5 μg / mL CRP + 25 μg / mL CRW.
[0063] 4. Statistical Analysis
[0064] Data were analyzed using GraphPad Prism 9.5 and expressed as mean ± standard deviation. One-way ANOVA and two-tailed t-tests were used to determine differences between groups, with P < 0.05 considered statistically significant.
[0065] III. Test Results
[0066] The results of human dermal papilla cell proliferation activity in each group are shown in Table 1. As can be seen from Table 1, both the total extract of Cyperus rotundus (CR) and the petroleum ether fraction (CRP) significantly enhanced the proliferation activity of human dermal papilla cells, and the effect was significantly dose-dependent. Among them, the petroleum ether fraction (CRP) showed the most significant proliferative effect, with cell viability reaching 175% at a concentration of 50 μg / mL, which was significantly better than that of the total extract of Cyperus rotundus (CR). The ethyl acetate fraction (CRE) at 25 μg / mL and the n-butanol fraction (CRB) at 50 μg / mL showed weak proliferative effects, while the water fraction (CRW) did not show a significant proliferative effect within the tested concentration range.
[0067] Compared with the petroleum ether fraction (CRP) at 12.5 μg / mL, no significant increase in the proliferation activity of human dermal papilla cells was observed in the groups treated with a combination of petroleum ether fraction (CRP) at 12.5 μg / mL and ethyl acetate fraction (CRE) at 12.5 μg / mL or 25 μg / mL. The proliferation activity of human dermal papilla cells was significantly increased in the groups treated with a combination of petroleum ether fraction (CRP) at 12.5 μg / mL and n-butanol fraction (CRB) at 12.5 μg / mL or 25 μg / mL. The proliferation activity of human dermal papilla cells was significantly increased in the groups treated with a combination of petroleum ether fraction (CRP) at 12.5 μg / mL and water fraction (CRW) at 12.5 μg / mL or 25 μg / mL. This combined administration demonstrated that although the n-butanol fraction (CRB) at 12.5 μg / mL and 25 μg / mL or the water fraction (CRW) at 12.5 μg / mL and 25 μg / mL alone did not have a significant proliferative effect on human dermal papilla cells, the combination with the petroleum ether fraction (CRP) at 12.5 μg / mL enhanced its proliferative effect on human dermal papilla cells, suggesting that the n-butanol fraction (CRB) or the water fraction (CRW) and the petroleum ether fraction (CRP) can synergistically promote the proliferation of human dermal papilla cells.
[0068] Table 1. Proliferative activity of human dermal papilla cells in each group
[0069]
[0070] Note: In Table 1, compared with the control group, * P < 0.05, **P < 0.01, *** P < 0.001, **** P < 0.0001; compared with the petroleum ether fraction (CRP) of 12.5 μg / mL, # P < 0.05.
[0071] Example 3: Cyperus rotundus active extract
[0072] This embodiment provides an active extract of Cyperus rotundus, which is the petroleum ether fraction prepared by the method of Example 1.
[0073] Example 4: Cyperus rotundus active extract
[0074] This embodiment provides a Cyperus rotundus active extract, which is a combination of the petroleum ether fraction and the n-butanol fraction prepared by the method of Example 1. The mass ratio of the petroleum ether fraction to the n-butanol fraction is 1:(0.5~2.5), preferably 1:(1~2), more preferably 1:1 or 1:2.
[0075] Example 5: Cyperus rotundus active extract
[0076] This embodiment provides a Cyperus rotundus active extract, which is a combination of the petroleum ether fraction and the aqueous fraction prepared by the method of Example 1. The mass ratio of the petroleum ether fraction to the aqueous fraction is 1:(0.5~2.5), preferably 1:(1~2), more preferably 1:1 or 1:2.
[0077] Example 6: A medicine for promoting hair follicle repair, promoting hair growth, and preventing or treating diseases caused by reduced hair follicle regeneration capacity.
[0078] This embodiment provides a medicine for promoting hair follicle repair, promoting hair growth, and preventing or treating diseases caused by reduced hair follicle regeneration capacity. It uses any one of the Cyperus rotundus active extracts selected from Examples 3-5 as the therapeutic ingredient, combined with pharmaceutically acceptable excipients, and is prepared into solutions, liniments, tinctures, gels, or lotions using conventional pharmaceutical processes. The resulting medicine can be used to promote hair follicle repair, or to promote hair growth, or to prevent or treat diseases caused by reduced hair follicle regeneration capacity, wherein the diseases caused by reduced hair follicle regeneration capacity are selected from one or more of scarring alopecia, non-scarring alopecia, and hereditary hair diseases.
[0079] in:
[0080] Cicatricial alopecia is selected from one or more of the following: lichen planus of hair, discoid lupus erythematosus, frontal fibrosis, folliculitis alopecia, scalp abscess dissecting folliculitis, centri-central cicatricial alopecia, mucinous alopecia, keratosis pilaris alopecia, classic pseudoalopecia areata, and secondary cicatricial alopecia.
[0081] Non-scarring alopecia is selected from one or more of the following: androgenetic alopecia, alopecia areata, telogen effluvium, anagen effluvium, postpartum alopecia, and trichotillomania.
[0082] Hereditary hair disorders are selected from one or more of the following: Marie Unna hereditary hypotrichosis, congenital alopecia, hypotrichosis with papules, and hypotrichosis.
[0083] Example 7: A cosmetic product used to promote hair follicle repair and hair growth.
[0084] This embodiment provides a cosmetic product that promotes hair follicle repair and hair growth. It uses any one of the Cyperus rotundus active extracts selected from Examples 3-5 as the ingredient for promoting hair follicle repair and hair growth. Conventional excipients acceptable in the cosmetic field are added, and the product is mixed, homogenized, and molded according to conventional cosmetic preparation processes to obtain the target cosmetic product. This cosmetic product is selected from any one of the following: shampoo, hair lotion, hair cream, scalp wash, conditioner, hair mask, hair treatment cream, hair conditioner, scalp serum, scalp essence, scalp ampoule, scalp spray, scalp toner, scalp scrub, scalp cream, hair growth liquid, anti-hair loss essence, hair root nourishing liquid, hair growth spray, leave-in conditioner, hair oil, hair spray, volumizing dry hair spray, hair styling gel, and hair wax. It can also be a scalp care shampoo and conditioner set, or a complete set of dandruff / oil control / anti-hair loss shampoo and conditioner products.
[0085] The purpose of the above embodiments is to specifically illustrate the substantive content of the present invention, but those skilled in the art should know that the scope of protection of the present invention should not be limited to the specific embodiments.
Claims
1. A Cyperus rotundus active extract, characterized in that: The active extract of Cyperus rotundus includes a weakly polar extract fraction of the total extract of Cyperus rotundus; the preparation method of the weakly polar extract fraction includes the following steps: take the total extract of Cyperus rotundus, add water to make an aqueous suspension, extract with a weakly polar organic solvent, collect the extract, concentrate and dry to obtain the weakly polar extract fraction; the weakly polar organic solvent is selected from one or more of petroleum ether, n-hexane, and cyclohexane. The preparation method of the total extract of Cyperus rotundus includes the following steps: taking Cyperus rotundus, extracting it with an alcohol-containing aqueous solution, and concentrating the extract to obtain the total extract of Cyperus rotundus; the volume percentage concentration of alcohol in the alcohol-containing aqueous solution is not less than 60%, 61%, 62%, 63%, 64%, 65%, 66%, 67%, 68%, 69%, 70%, 71%, 72%, 73% or 74%, and not higher than 76%, 77%, 78%, 79%, 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89% or 90%; The alcohol is selected from one or more of ethanol and methanol.
2. The Cyperus rotundus active extract according to claim 1, characterized in that: The active extract of Cyperus rotundus also includes the aqueous phase fraction of the total extract of Cyperus rotundus; the preparation method of the aqueous phase fraction includes the following steps: take the total extract of Cyperus rotundus, add water to make an aqueous suspension, extract it sequentially with a weakly polar organic solvent, a moderately polar organic solvent, and a moderately strong polar organic solvent, collect the remaining aqueous suspension, concentrate and dry it to obtain the aqueous phase fraction; The weakly polar organic solvent is selected from one or more of petroleum ether, n-hexane, and cyclohexane; the moderately polar organic solvent is selected from one or more of ethyl acetate, chloroform, and dichloromethane; and the moderately strongly polar organic solvent is selected from one or more of n-butanol, isobutanol, and sec-butanol.
3. The Cyperus rotundus active extract according to claim 2, characterized in that: The mass ratio of the weakly polar extraction fraction to the aqueous phase fraction is 1:(0.5~2.5).
4. The Cyperus rotundus active extract according to claim 3, characterized in that: The mass ratio of the weakly polar extraction fraction to the aqueous phase fraction is 1:(1~2).
5. The Cyperus rotundus active extract according to claim 1, characterized in that: The active extract of Cyperus rotundus also includes a medium-to-strong polarity extract fraction of the total extract of Cyperus rotundus; the preparation method of the medium-to-strong polarity extract fraction includes the following steps: take the total extract of Cyperus rotundus, add water to make an aqueous suspension, and extract it sequentially with a weakly polar organic solvent, a medium-polar organic solvent, and a medium-to-strong polar organic solvent, collect the medium-to-strong polar organic solvent extract, concentrate and dry it to obtain the medium-to-strong polarity extract fraction. The weakly polar organic solvent is selected from one or more of petroleum ether, n-hexane, and cyclohexane; the moderately polar organic solvent is selected from one or more of ethyl acetate, chloroform, and dichloromethane; and the moderately strongly polar organic solvent is selected from one or more of n-butanol, isobutanol, and sec-butanol.
6. The Cyperus rotundus active extract according to claim 5, characterized in that: The mass ratio of the weakly polar extraction fraction to the medium-strong polar extraction fraction is 1:(0.5~2.5).
7. The Cyperus rotundus active extract according to claim 6, characterized in that: The mass ratio of the weakly polar extraction fraction to the medium-strong polar extraction fraction is 1:(1~2).
8. The use of the Cyperus rotundus active extract according to any one of claims 1 to 7 in the preparation of products that promote hair follicle repair, or the use of the Cyperus rotundus active extract according to any one of claims 1 to 7 in the preparation of products that promote hair growth, or the use of the Cyperus rotundus active extract according to any one of claims 1 to 7 in the preparation of products that prevent or treat diseases caused by reduced hair follicle regeneration capacity.
9. The application according to claim 8, characterized in that: The diseases caused by reduced hair follicle regeneration capacity are selected from one or more of scarring alopecia, non-scarring alopecia, and hereditary hair diseases; in: Cicatricial alopecia is selected from one or more of the following: lichen planus of hair, discoid lupus erythematosus, frontal fibrosis, folliculitis alopecia, scalp abscess dissecting folliculitis, centri-central cicatricial alopecia, mucinous alopecia, keratosis pilaris alopecia, classic pseudoalopecia areata, and secondary cicatricial alopecia. Non-scarring alopecia is selected from one or more of the following: androgenetic alopecia, alopecia areata, telogen effluvium, anagen effluvium, postpartum alopecia, and trichotillomania. Hereditary hair disorders are selected from one or more of the following: Marie Unna hereditary hypotrichosis, congenital alopecia, hypotrichosis with papules, and hypotrichosis.
10. The application according to claim 8 or 9, characterized in that: The products mentioned are pharmaceuticals, cosmetics, health products, or functional foods.